

## Special Issue

# Targeted Nanoradiopharmaceuticals as a Molecular Approach for Theranostic Applications

### Message from the Guest Editors

The field of nanoparticle-based radiopharmaceuticals holds great promise for the diagnosis and treatment of cancer and other diseases. Nanoparticles can be used to deliver radionuclides, cytotoxic drugs, or imaging agents, offering multimodal platforms as integral approaches in the field of nuclear medicine. This Special Issue aims to explore strategies to improve targeting efficiency and to develop methods for encapsulating components that ensure safety and efficacy, in order to propose new approaches for the clinical translation phase. The sub-topics to be covered within this Special Issue are as follows:

- Radiopharmaceuticals based on organic nanoparticles for combined therapies;
- Radiopharmaceuticals based on metallic nanoparticles for theranostic purposes;
- Radiolabeled nanoparticles for diagnosis or therapy.

### Guest Editors

Dr. Blanca Ocampo García

Dr. Enrique Morales-Avila

Dr. Laura Melendez-Alafort

### Deadline for manuscript submissions

closed (31 March 2025)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/199444](https://mdpi.com/si/199444)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).